Clinical Trials Logo

Clinical Trial Summary

Objective: To evaluate the efficacy and safety of Ningmitai Capsules and Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release Capsules. Study design: A multicenter, prospective, randomized, double-blind, positive controlled clinical study. Interventions: Group A: Oral Tamsulosin Hydrochloride Capsules and Ningmitai Capsules placebo for 12 weeks. Group B: Oral l Silodosin Capsules and Ningmitai Capsules placebo for 12 weeks. Group C: Oral l Silodosin Capsules and Ningmitai Capsules for 12 weeks.


Clinical Trial Description

Sample size: 312 ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05551221
Study type Interventional
Source Xintian Pharmaceutical
Contact Peiling Shi
Phone +8619821240029
Email lc-spl@xtyyoa.com
Status Recruiting
Phase Phase 4
Start date July 18, 2022
Completion date December 31, 2026